N05AH03 olanzapine
NERVOUS SYSTEM ›PSYCHOLEPTICS ›ANTIPSYCHOTICS ›Diazepines, oxazepines, thiazepines and oxepines
健保收載品項 TFDA 在效許可證 44 FDA 已核准 健保給付條款 4
台灣藥品與外觀
健保收載品名："台裕"憂立平口崩片10毫克、"台裕"憂立平口崩片5毫克、"新瑞"納得復膜衣錠10毫克、"西班牙禮來"金普薩膜衣錠 10 毫克、"西班牙禮來"金普薩膜衣錠 5 毫克、優散平口溶錠10毫克、優散平口溶錠5毫克、吉博薩口溶錠10毫克、吉博薩口溶錠5毫克、吉博薩膜衣錠10毫克、吉博薩膜衣錠5毫克、安保普能平口溶錠10毫克、安保普能平口溶錠5毫克、思克明膜衣錠 5 毫克、思克明膜衣錠10毫克、思克明膜衣錠5毫克
無外觀照
奧氮平
無外觀照
奧氮平
無外觀照
奧氮平
無外觀照
思克明膜衣錠 5 毫克
資料來源：食藥署「西藥許可證」＋「藥品 ATC 碼」＋「藥品外觀」＋「藥品仿單或外盒」開放資料。外觀照與仿單連結指向食藥署原始檔。
適應症
台灣 TFDA 核准適應症
- 思覺失調症及其他明顯有正性及/或負性之精神病、雙極性疾患之躁期發作、預防雙極性疾患之復發。
- 思覺失調症及其它明顯有正性及/或負性之精神病、雙極性疾患之躁期發作、預防雙極性疾患之復發。
- 思覺失調症及其它明顯有正性及∕或負性之精神病、雙極性疾患之躁期發作、預防雙極性疾患之復發。
- 成人思覺失調症及成人雙極性第I型躁症之激動症狀。
- 抗精神分裂藥物。
- 思覺失調症。
- 抗精神病藥。
- 精神分裂症。
美國 FDA 適應症（英文原文對照）
1 INDICATIONS AND USAGE Olanzapine is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As Olanzapine and Fluoxetine in Combination for the: Treatment of depressive episodes associated with bipolar I disorder. ( 1.5 ) Efficacy was established with Symbyax (olanzapine and fluoxetine in combination); refer to the product label for Symbyax. Treatment of treatment resistant depression. ( 1.6 ) Efficacy was established with Symbyax (olanzapine and fluoxetine in combination) in adults; refer to the product label for Symbyax. 1.1 Schizophrenia Oral olanzapine is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see Clinical Studies (14.1) ]. When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions (5.5) ]. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one monotherapy maintenance trial. In adolescent patients with manic or mixed episodes associated with bipolar I disorder (ages 13-17), efficacy was established in one 3-week trial [see Clinical Studies (14.2) ]. When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions (5.5) ]. Adjunctive Therapy to Lithium or Valproate — Oral olanzapine is indicated for the treatment of manic or mixed episodes associated with bipolar I disorder as an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically evaluated in controlled trials [see Clinical Studies (14.2) ]. 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders; however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, pediatric patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder should be part of a total treatment program that often includes psychological, educational and social interventions. 1.5 Olanzapine and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder Oral olanzapine and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder. 1.6 Olanzapine and Fluoxetine in Combination: Treatment Resistant Depression Oral olanzapine and fluoxetine in combination is indicated for the treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode), based on clinical studies in adult patients. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine monotherapy is not indicated for the treatment of treatment resistant depression.
1.1 Schizophrenia Oral olanzapine is indicated for the treatment of schizophrenia. Efficacy was established in three clinical trials in adult patients with schizophrenia: two 6-week trials and one maintenance trial. In adolescent patients with schizophrenia (ages 13-17), efficacy was established in one 6-week trial [see Clinical Studies (14.1) ]. When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions (5.5) ].
1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral olanzapine is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. Efficacy was established in three clinical trials in adult patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one monotherapy maintenance trial. In adolescent patients with manic or mixed episodes associated with bipolar I disorder (ages 13-17), efficacy was established in one 3-week trial [see Clinical Studies (14.2) ]. When deciding among the alternative treatments available for adolescents, clinicians should consider the increased potential (in adolescents as compared with adults) for weight gain and dyslipidemia. Clinicians should consider the potential long-term risks when prescribing to adolescents, and in many cases this may lead them to consider prescribing other drugs first in adolescents [see Warnings and Precautions (5.5) ]. Adjunctive Therapy to Lithium or Valproate — Oral olanzapine is indicated for the treatment of manic or mixed episodes associated with bipolar I disorder as an adjunct to lithium or valproate. Efficacy was established in two 6-week clinical trials in adults. The effectiveness of adjunctive therapy for longer-term use has not been systematically evaluated in controlled trials [see Clinical Studies (14.2) ].
1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders; however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, pediatric patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder should be part of a total treatment program that often includes psychological, educational and social interventions.
1.5 Olanzapine and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder Oral olanzapine and fluoxetine in combination is indicated for the treatment of depressive episodes associated with bipolar I disorder, based on clinical studies. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine monotherapy is not indicated for the treatment of depressive episodes associated with bipolar I disorder.
1.6 Olanzapine and Fluoxetine in Combination: Treatment Resistant Depression Oral olanzapine and fluoxetine in combination is indicated for the treatment of treatment resistant depression (major depressive disorder in patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode), based on clinical studies in adult patients. When using olanzapine and fluoxetine in combination, refer to the Clinical Studies section of the package insert for Symbyax. Olanzapine monotherapy is not indicated for the treatment of treatment resistant depression.
資料來源：食藥署西藥許可證適應症（中文）、openFDA US SPL（英文，僅供對照）。
健保給付規定
直接適用條款
§ 1.2.2.2 Second generation antipsychotics(簡稱第二代抗精神病藥品，如
神經系統藥物 › 精神治療劑
Second generation antipsychotics(簡稱第二代抗精神病藥品，如clozapine、olanzapine、risperidone、quetiapine、amisulpride、ziprasidone、aripiprazole、paliperidone、lurasidone、brexpiprazole等)：(91/9/1、92/1/1、92/7/1、94/1/1、95/10/1、97/5/1、99/10/1、106/1/1、109/1/1、109/6/1、112/7/1)
1.本類製劑之使用需符合下列條件(95/10/1、97/5/1、99/10/1、106/1/1、109/1/1、112/7/1)：
(1)開始使用「第二代抗精神病藥品」時需於病歷記載：醫療理由或診斷。(112/7/1)。
(2)日劑量超過下列治療劑量時，需於病歷記載理由：
clozapine 400 mg/day
risperidone 6 mg/day
olanzapine 20 mg/day
quetiapine 600 mg/day
amisulpride 800mg/day (92/1/1)
ziprasidone 120mg/day (92/7/1)
aripiprazole 15mg/day (94/1/1)
paliperidone 12mg/day (97/5/1）
lurasidone 120mg/day (106/1/1）
brexpiprazole 4mg/day (109/1/1)
2.本類藥品除quetiapine緩釋劑型及lurasidone外，不得使用於雙極性疾患之鬱症發作。(95/10/1、109/6/1)
3.Olanzapine用於預防雙極性疾患復發時，限lithium、carbamazepine、valproate等藥品至少使用兩種以上，治療無效或無法耐受副作用時使用。(95/10/1) 歷史演變（11 次異動）
| 生效日 | 異動說明 |
|---|---|
| 91/9/1 | legacy_boan_parsed:ch01.txt |
| 92/1/1 | legacy_boan_parsed:ch01.txt |
| 92/7/1 | legacy_boan_parsed:ch01.txt |
| 94/1/1 | legacy_boan_parsed:ch01.txt |
| 95/10/1 | legacy_boan_parsed:ch01.txt |
| 97/5/1 | legacy_boan_parsed:ch01.txt |
| 99/10/1 | legacy_boan_parsed:ch01.txt |
| 106/1/1 | legacy_boan_parsed:ch01.txt |
| 109/1/1 | legacy_boan_parsed:ch01.txt |
| 109/6/1 | legacy_boan_parsed:ch01.txt |
| 112/7/1 | legacy_boan_parsed:ch01.txt |
上層 ATC 繼承條款
繼承自 ATC N05A
§ 0.4 注射藥品之使用原則：
通則 › 通則
四、注射藥品之使用原則： （一）注射藥品使用時機，應以經醫師診斷後，判斷病情需要且病人不能口服，或口服仍不能期待其有治療效果，記明於病歷表者，方得為之。(86/1/1) （二）因病情需要，經醫師指導使用方法由病人持回注射之藥品包括： 1. 治療糖尿病之insulin及GLP-1受體促效劑。(109/12/1) 2. CAPD使用之透析液。 3. CAPD使用之抗生素及抗凝血劑（至多攜回二週）。 4. Desferrioxamine（如 Desferal）。 5. 慢性腎臟功能衰竭，使用紅血球生成素（至多攜回二週，如因特殊病情需要，需敘明理由，得以臨床實際需要方式給藥，惟一個月不超過20,000U（如Eprex、Recormon）或100mcg（如Aranesp、Mircera）為原則）。(98/9/1) 6. 治療白血病使用之α-interferon（至多攜回二週）。 7. G-CSF (如filgrastim；lenograstim）(至多攜回六天）。(98/11/1) 8. 生長激素 (human growth hormone)（至多攜回一個月）。 9. 門診之血友病人得攜回二\~三劑量(至多攜回一個月)第八、第九凝血因子、繞徑治療藥物、第十三凝血因子備用，繼續治療時，比照化療以「療程」方式處理，並查驗上次治療紀錄（如附表十八之一─全民健康保險血友病患者使用第八、第九凝血因子在家治療紀錄等）及申報費用時上傳上述治療紀錄表電子檔。醫療機構、醫師開立使用血液製劑時，應依血液製劑條例之規定辦理。（86/9/1、92/5/1、100/4/1、108/10/1、109/2/1) 10. 於醫院內完成調配之靜脈營養輸液(TPN)，或不需調配之靜脈營養輸液，可攜回使用。(85/10/1、93/12/1、111/1/1) 11. 肢端肥大症病人使用之octreotide、lanreotide (如Sandostatin、Somatuline等) 至多攜回一個月，另octreotide (如Sandostatin等)需個案事前報准 (93/12/1)。lanreotide inj 30 mg (如Somatuline) 每次注射間隔兩週 (88/6/1)，octreotide LAR (如Sandostatin LAR Microspheres for Inj.) 每次注射間隔四週 (89/7/1)。 12. 結核病病人持回之streptomycin、kanamycin及enviomycin注射劑（至多攜回二週）。（86/9/1） 13. 抗精神病長效針劑（至多攜回三個月）。（87/4/1、109/6/1） 14. 低分子量肝凝素注射劑：金屬瓣膜置換後之懷孕病患，可准予攜回低分子量肝凝素注射劑自行注射，但至多攜回兩週。（90/11/1） 15. Apomorphine hydrochloride 10mg/mL（如Apo-Go Pen）：限使用於巴金森氏病後期產生藥效波動（on-and-off）現象，且經使用其他治療方式無法改善之病患使用，每人每月使用量不得超過20支。（91/2/1、99/11/1） 16. 罹患惡性貧血（pernicious anemia）及維生素B12缺乏病患，如不能口服者或口服不能吸收者，得攜回維生素B12注射劑，每次以一個月為限，且每三個月應追蹤一次。(91/4/1) 17. 患者初次使用aldesleukin (如Proleukin Inj) 治療期間（第一療程），應每週發藥，俾回診觀察是否有無嚴重之副作用發生。第一療程使用若未發生嚴重副作用，在第二療程以後可攜回兩週之處方量。(91/12/1) 18. 慢性病毒性B型肝炎、慢性病毒性C型肝炎所使用之長效型干擾素或短效型干擾素，至多攜回四週之使用量。(92/10/1) 19. 類風濕關節炎、僵直性脊椎炎、乾癬、乾癬性周邊關節炎、乾癬性脊椎病變與克隆氏症病患使用etanercept、adalimumab、abatacept、tocilizumab、opinercept、certolizumab、brodalumab等生物製劑皮下注射劑，經事前審查核准後，在醫師指導下，至多可攜回四週之使用量。(93/8/1、109/10/1) 20. (刪除) (109/12/1) 21. (刪除) (109/12/1) 22. 含teriparatide成分注射劑。(103/9/1) 23. 含interferon beta-1a 成分注射劑。(103/9/1) 24. 含interferon beta-1b成分注射劑。(103/9/1) 25. 含glatiramer成分注射劑。(103/9/1) 26. Fondaparinux（如Arixtra）用於靜脈血栓高危險病患，接受人工髖或膝關節置換術或再置換術後，預防其術後之靜脈血栓(VTE)。（111/3/1) （三）電解質及營養靜脈補充輸液之使用，應說明理由並有明確需要，以積極治療為目的，始得為之。 （四）癌症病人使用之morphine及化學治療藥品，於院內經醫師或藥師完成調劑作業後，亦可由病人攜回使用。（85/10/1）
歷史演變（26 次異動）
| 生效日 | 異動說明 |
|---|---|
| 85/10/1 | legacy_boan_parsed:ch00_tonze.txt |
| 86/1/1 | legacy_boan_parsed:ch00_tonze.txt |
| 86/9/1 | legacy_boan_parsed:ch00_tonze.txt |
| 87/4/1 | legacy_boan_parsed:ch00_tonze.txt |
| 88/6/1 | legacy_boan_parsed:ch00_tonze.txt |
| 89/7/1 | legacy_boan_parsed:ch00_tonze.txt |
| 90/11/1 | legacy_boan_parsed:ch00_tonze.txt |
| 91/2/1 | legacy_boan_parsed:ch00_tonze.txt |
| 91/4/1 | legacy_boan_parsed:ch00_tonze.txt |
| 91/12/1 | legacy_boan_parsed:ch00_tonze.txt |
| 92/5/1 | legacy_boan_parsed:ch00_tonze.txt |
| 92/10/1 | legacy_boan_parsed:ch00_tonze.txt |
| 93/8/1 | legacy_boan_parsed:ch00_tonze.txt |
| 93/12/1 | legacy_boan_parsed:ch00_tonze.txt |
| 98/9/1 | legacy_boan_parsed:ch00_tonze.txt |
| 98/11/1 | legacy_boan_parsed:ch00_tonze.txt |
| 99/11/1 | legacy_boan_parsed:ch00_tonze.txt |
| 100/4/1 | legacy_boan_parsed:ch00_tonze.txt |
| 103/9/1 | legacy_boan_parsed:ch00_tonze.txt |
| 108/10/1 | legacy_boan_parsed:ch00_tonze.txt |
| 109/2/1 | legacy_boan_parsed:ch00_tonze.txt |
| 109/6/1 | legacy_boan_parsed:ch00_tonze.txt |
| 109/10/1 | legacy_boan_parsed:ch00_tonze.txt |
| 109/12/1 | legacy_boan_parsed:ch00_tonze.txt |
| 111/1/1 | legacy_boan_parsed:ch00_tonze.txt |
| 111/3/1 | legacy_boan_parsed:ch00_tonze.txt |
§ 0.4.2.13 long_acting_antipsychotic
通則 › 通則
抗精神病長效針劑（至多攜回三個月）。（87/4/1、109/6/1）
§ 1.2.2 抗精神病藥品 — narrative parent
神經系統藥物 › 精神治療劑
抗精神病劑 (Antipsychotics)
實證補充
本藥品尚無實證補充整理（未來新增 Review／指引知識時補列）。
台灣藥品與適應症：食藥署西藥許可證＋ATC＋外觀＋仿單開放資料 · FDA：openFDA US SPL · 健保給付：健保署「全民健康保險藥品給付規定」（更新日 2026-06-09）· 實證補充：人工彙整。 本頁為資訊整理，實際給付與適應症以主管機關公告為準。